WO2012131092A3 - Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages - Google Patents

Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages Download PDF

Info

Publication number
WO2012131092A3
WO2012131092A3 PCT/EP2012/055962 EP2012055962W WO2012131092A3 WO 2012131092 A3 WO2012131092 A3 WO 2012131092A3 EP 2012055962 W EP2012055962 W EP 2012055962W WO 2012131092 A3 WO2012131092 A3 WO 2012131092A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
egfr antibody
nonresponse
kits
prediction
Prior art date
Application number
PCT/EP2012/055962
Other languages
French (fr)
Other versions
WO2012131092A2 (en
Inventor
Paulina PECHANSKA
Bernd Hinzmann
Tobias Mayr
André ROSENTHAL
Original Assignee
Signature Diagnostics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11161244A external-priority patent/EP2508619A1/en
Application filed by Signature Diagnostics Ag filed Critical Signature Diagnostics Ag
Publication of WO2012131092A2 publication Critical patent/WO2012131092A2/en
Publication of WO2012131092A3 publication Critical patent/WO2012131092A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The invention pertains to a method for predicting responsiveness of a human patient in need of treatment with an anti-EGFR antibody to such treatment based on a biological sample. According to the invention, this method comprises: determining the mutation status of KRAS, BRAF and PIK3CA, and concluding based on the mutation status whether the subject will be responsive to treatment with an anti-EGFR antibody.
PCT/EP2012/055962 2011-03-31 2012-04-02 Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages WO2012131092A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11160641.4 2011-03-31
EP11160641 2011-03-31
EP11161244A EP2508619A1 (en) 2011-04-05 2011-04-05 Method and kits for the prediction of response/nonresponse to the treatment with an anti-EGFR antibody in patients with colorectal cancer of all UICC stages
EP11161244.6 2011-04-05

Publications (2)

Publication Number Publication Date
WO2012131092A2 WO2012131092A2 (en) 2012-10-04
WO2012131092A3 true WO2012131092A3 (en) 2012-11-22

Family

ID=46026773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/055962 WO2012131092A2 (en) 2011-03-31 2012-04-02 Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages

Country Status (1)

Country Link
WO (1) WO2012131092A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014063206A1 (en) * 2012-10-26 2014-05-01 The University Of Queensland Methods for classifying tumors and uses therefor
CN103773889B (en) * 2014-02-20 2015-07-15 武汉大学 HRM (high resolution melting) method and kit for clinically detecting EGFR (epidermal growth factor receptor) gene mutation
ES2844229T3 (en) 2014-05-13 2021-07-21 Univ Texas Gene mutations and copy number alterations of EGFR, KRAS, and MET
LT3198026T (en) * 2014-08-07 2020-01-27 Pharmassist Ltd Method of determining pik3ca mutational status in a sample
RU2552483C1 (en) * 2014-08-11 2015-06-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Method of analysis of somatic mutations in genes egfr, kras and braf using lna-blocking multiplex pcr and subsequent hybridisation with oligonucleotide biological microchip (biochip)
KR102600347B1 (en) * 2015-07-17 2023-11-09 주식회사 젠큐릭스 Composition for detecting mutations of NRAS gene and kit comprising the same

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Affymetrix SNP arrays 500k, SNP-5 and SNP6 comprise SNP probes for BRAF", 14 December 2009 (2009-12-14), XP055004965, Retrieved from the Internet <URL:http://www.affymetrix.com/estore/analysis/index.affx;jsessionid=3BBF81ECD8AD12C68443C6D3E972EECF?category=34005&categoryIdClicked=34005&rootCategoryId=34005&navMode=34005&aId=netAffxNav> [retrieved on 20110818] *
"Affymetrix SNP arrays 500k, SNP-5 and SNP6 comprise SNP probes for KRAS", 14 December 2009 (2009-12-14), XP055004967, Retrieved from the Internet <URL:http://www.affymetrix.com/estore/analysis/index.affx;jsessionid=3BBF81ECD8AD12C68443C6D3E972EECF?category=34005&categoryIdClicked=34005&rootCategoryId=34005&navMode=34005&aId=netAffxNav> [retrieved on 20110818] *
"Affymetrix SNP arrays 500k, SNP-5 and SNP6 comprise SNP probes for PIK3CA", 14 December 2009 (2009-12-14), XP055004968, Retrieved from the Internet <URL:http://www.affymetrix.com/estore/analysis/index.affx;jsessionid=3BBF81ECD8AD12C68443C6D3E972EECF?category=34005&categoryIdClicked=34005&rootCategoryId=34005&navMode=34005&aId=netAffxNav> [retrieved on 20110818] *
A. SARTORE-BIANCHI ET AL: "Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer", CANCER TREATMENT REVIEWS, vol. 36, 1 November 2010 (2010-11-01), pages S1 - S5, XP055004988, ISSN: 0305-7372, DOI: 10.1016/S0305-7372(10)70012-8 *
ANANTHARAMAN RAMANI ET AL: "Validation of pooled genotyping on the Affymetrix 500 k and SNP6.0 genotyping platforms using the polynomial-based probe-specific correction", BMC GENETICS, BIOMED CENTRAL, GB, vol. 10, no. 1, 14 December 2009 (2009-12-14), pages 82, XP021065948, ISSN: 1471-2156 *
CHAI HIGH SENG ET AL: "Spatial normalization improves the quality of genotype calling for Affymetrix SNP 6.0 arrays", BMC BIOINFORMATICS, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 29 June 2010 (2010-06-29), pages 356, XP021071683, ISSN: 1471-2105, DOI: 10.1186/1471-2105-11-356 *
DE ROOCK W ET AL: "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 11, no. 8, 1 August 2010 (2010-08-01), pages 753 - 762, XP027598757, ISSN: 1470-2045, [retrieved on 20100801], DOI: 10.1016/S1470-2045(10)70130-3 *
DI NICOLANTONIO FEDERICA ET AL: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 DEC 2008 LNKD- PUBMED:19001320, vol. 26, no. 35, 10 December 2008 (2008-12-10), pages 5705 - 5712, XP009123180, ISSN: 1527-7755 *
M. S. BANCK ET AL: "Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer", CLINICAL CANCER RESEARCH, vol. 15, no. 24, 15 December 2009 (2009-12-15), pages 7492 - 7501, XP055004985, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-0188 *
SARTORE-BIANCHI ANDREA ET AL: "PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies", CANCER RESEARCH / AMERICAN ASSOCIATION FOR CANCER RESEARCH, AACR, PHILADELPHIA, PA, vol. 69, no. 5, 1 March 2009 (2009-03-01), pages 1851 - 1857, XP002547209, ISSN: 1538-7445, [retrieved on 20090217], DOI: 10.1158/0008-5472.CAN-08-2466 *
YIN-HSUN FENG ET AL: "Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells", CANCER SCIENCE, vol. 101, no. 9, 1 September 2010 (2010-09-01), pages 2033 - 2038, XP055004987, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2010.01637.x *

Also Published As

Publication number Publication date
WO2012131092A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
WO2012131092A3 (en) Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
PH12018500515A1 (en) Therapeutic cd47 antibodies
WO2010145796A3 (en) Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2009137832A3 (en) Autoantibodies in the detection and treatment of cancer
WO2012141844A3 (en) Methods predicting risk of an adverse clinical outcome
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2010085542A3 (en) Biomarkers related to age-related macular degeneration (amd)
EP3411689A4 (en) Analyte system and method for determining hemoglobin parameters in whole blood
WO2010091049A3 (en) Diagnosis and treatment of cancer
NZ609824A (en) Immunochromatography devices, methods and kits
WO2010092190A3 (en) Prediction of response to platinum-based therapy
WO2013071012A3 (en) Personalized strategic cancer treatment
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy
AP2011005905A0 (en) Device and method for the verification and quantitative analysis of analytes, particularly mycotoxins.
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
MX2013011431A (en) Methods for predicting and improving the survival of gastric cancer patients.
CA2888908A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
WO2010054377A3 (en) Fully human antibodies against n-cadherin
WO2010009129A3 (en) Methods of treating autoimmune diseases using cd4 antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12718610

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12718610

Country of ref document: EP

Kind code of ref document: A2